| abstract |
Disclosed is a WDR5 protein-protein interaction inhibitor, containing a compound with a structure as shown in general formula (I). Experiments show that the inhibitor acts on the WDR5 protein and interacting proteins thereof, including, but not limited to, MLL, selectively inhibits the proliferation of leukemia cells, and inhibits, at a cellular level, the methylation of H3K4 and the expression of a downstream Hox/Meis-1 gene. Also disclosed are a method for preparing the inhibitor and the use thereof in the preparation of a drug for treating acute leukemia and other related diseases. |